ResourcesVendorsRoche2841 Scott Blvd Santa Clara, CA, USA 95050Latest from RocheMolecular DiagnosticsRoche launches ISH mRNA Probe Cocktail assayBy LabPulse.com staff writersRoche said the assay can assess small biopsies and reduce the need for additional biopsies, especially in situations where lymphoma was not originally suspected.June 20, 2024CollaborationRoche, Ascidian to develop gene therapies for neurological diseasesBy LabPulse.com staff writersRoche has announced a research collaboration and licensing agreement with biotech firm Ascidian Therapeutics to develop gene therapies for neurological diseases.June 19, 2024CollaborationALZpath, Roche sign licensing agreement for dementia biomarkerBy LabPulse.com staff writersALZpath has signed a licensing agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize a diagnostic blood test for Alzheimer's disease that will be offered on the Roche Elecsys platform.June 12, 2024FDA ClearanceRoche garners FDA EUA for 4-in-1 respiratory panelBy LabPulse.com staff writersRoche has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Cobas Liat SARS-CoV-2, influenza A/B, and RSV nucleic acid test.June 10, 2024Diagnostic TechnologiesRoche extends partnership, will offload GenentechBy LabPulse.com staff writersJapan-based Hitachi High-Tech and Switzerland-based Roche have extended their IVD development support partnership for another 10 years, the companies announced.May 30, 2024Neurodegenerative DiseaseTarget ALS launches new data portal for researchBy Matt LimbA nonprofit medical research foundation has launched a data portal designed to help spur scientific breakthroughs for the disease amyotrophic lateral sclerosis (ALS).April 23, 2024Regulatory ApprovalRoche, Lilly Alzheimer's blood test granted FDA breakthrough device designationBy LabPulse.com staff writersThe Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).April 11, 2024Regulatory ApprovalRoche's breast cancer CDx receives CE MarkBy LabPulse.com staff writersRoche has received the CE Mark for the first companion diagnostic (CDx) test to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with Enhertu.April 10, 2024FinancingFreenome raises $254M in funding to advance cancer test pipelineBy LabPulse.com staff writersBiotech firm Freenome has raised $254 million in new funding from new and existing investors to accelerate its pipeline of early detection cancer tests for its multiomics platform.February 15, 2024Trends and FinanceRoche confirms product development team layoffsBy LabPulse.com staff writersRoche has confirmed that it plans to lay off several hundred employees from its product development team but has not given specific details.February 13, 2024Mergers & AcquisitionsRoche signs $350M deal to buy POC technology from LumiraDxBy LabPulse.com staff writersRoche has entered into a definitive agreement to purchase point-of care (POC) technologies from LumiraDx for $295 million, with an additional payment of up to $55 million to fund the POC diagnostics platform business until the transaction closes.January 3, 2024SequencingPharma companies back project to create largest African ancestry genomics research databaseBy Nick Paul TaylorAstraZeneca, Novo Nordisk, Regeneron, and Roche have backed a project to create the largest African ancestry genomics research database.October 25, 2023CollaborationBoehringer Ingelheim, Thermo Fisher to collaborate on CDx development for NSCLCBy LabPulse.com staff writersBoehringer Ingelheim and Thermo Fisher have formed a partnership to develop companion diagnostic (CDx) tests for identifying patients with non-small cell lung cancer (NSCLC) with specific genomic mutations who may benefit from targeted therapies.October 19, 2023ValidationRoche’s Alecensa improves survival in postsurgery lung cancer patients in late-phase trialBy Nick Paul TaylorRoche’s Alecensa has improved disease-free survival in non-small cell lung cancer patients, positioning the Swiss drugmaker to apply to expand the product label.September 8, 2023Clinical TrialRoche data release raises hopes TIGIT drugs can improve lung cancer survivalBy Nick Paul TaylorRoche's inadvertent release of interim data from its ongoing late-phase clinical trial has raised hopes that its anti-TIGIT immunotherapy may improve the survival rate of lung cancer patients.August 25, 2023